ASCO Updates Guidelines on Bone-Modifying Drugs in Breast Cancer

Publication
Article
Oncology Nursing NewsApril 2011
Volume 5
Issue 2

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

The American Society of Clinical Oncology (ASCO) has developed a new set of recommendations for using bone-modifying agents for patients with metastatic breast cancer amid growing therapeutic options and fresh concerns about serious skeletal-related events.

The ASCO panel said only patients with evidence of bone metastases should be treated with the therapy, and that there is insufficient evidence to demonstrate greater efficacy of 1 bone-modifying agent over another.

The options are: denosumab 120 mg subcutaneously every 4 weeks; intravenous pamidronate 90 mg over no fewer than 2 hours; or zoledronic acid 4 mg over no fewer than 15 minutes every 3 to 4 weeks. Serum creatinine should be monitored before each dose, and patients should receive dental care before and during therapy.

(Full Story)

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos
Photo of a woman wearing a blazer and a colorful scarf in front of a blue background
Photo of a woman with red hair and glasses wearing a black blouse and cross necklace in front of a dark blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of a woman with her hair in a ponytail in front of a light blue background
Photo of a man wearing a suit with a blue tie in front of a dark blue background
Photo of Hope Rugo, MD
Image of a woman with blond hair in front of a dark blue background
Photo of a woman smiling in front of a dark blue background
Image of a woman with blonde hair wearing a black shirt in front of a blue background
Image of a woman with light brown hair wearing glasses with a blue background